Remove Engineering Remove Immune Response Remove Regulations
article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation small molecules. Molecular engineering approaches Most CNS disorders involve abnormal gene expression, and molecular engineering is one of the most powerful tools to address this issue.

article thumbnail

Leveraging agonist antibodies to address immunological diseases

Drug Target Review

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. This approach augments the strength of achieving immune homeostasis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR agonists, including antibodies, are shaping the future of metabolic care

Drug Target Review

G protein-coupled receptors (GPCRs) represent a cornerstone of modern drug discovery due to their crucial role in regulating human physiology and their involvement in numerous diseases. The MC4R-based ConfoGen was used to immunize llamas, resulting in an immune response that generated a highly diverse panel of MC4R-specific agonists.

article thumbnail

A Visual Guide to Gene Delivery

Codon

The first of these components is the therapeutic genetic payload, or cargo, which is designed to correct or regulate the disease-causing mutation, whether that means offering a healthy copy of a mutated gene or delivering precision-editing tools like CRISPR. In contrast, the eye, with its lower immune activity, offers a more receptive target.

article thumbnail

A Visual Guide to Genome Editors

Codon

The core of the CRISPR immune response is a guide RNA (gRNA) that binds to a CRISPR-associated (Cas) protein. Researchers have engineered more specific enzymes — possessing drastically reduced off-target effects — by altering either the structure of the Cas9 protein itself or its gRNA. Join Asimov Press.

DNA
article thumbnail

FDA takes major step to ease access to CAR-T therapy

BioPharma Drive: Drug Pricing

These medicines are made from a patient’s own immune cells, extracted from the body and engineered in a lab to hunt down specific proteins found on the surface of malignant clones. For some people with leukemia, lymphoma or multiple myeloma, they can prompt powerful responses and even long-lasting remission.

article thumbnail

Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering

Drug Target Review

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.